Article
Food Science & Technology
Andrea Santamato
Summary: In recent years, there has been increasing interest in using higher doses of botulinum toxin type A for severe spasticity in the upper and lower limbs. While one study has investigated the safety and tolerability of using a dose of up to 800 U, there is limited evidence on the reasons for using high doses of botulinum toxin. This short communication highlights the benefits of higher doses for individuals with upper and lower limb spasticity.
Review
Food Science & Technology
Thanh-Nhan Doan, Mei-Ying Kuo, Li-Wei Chou
Summary: A systematic review and meta-analysis found that BoNT-A can improve muscle tone and functional outcomes of patients with post-stroke lower extremity spasticity, particularly for the most common spastic pattern. However, further research is needed to determine the optimal dosage and establish a combined rehabilitation program.
Article
Biology
Ana Maria Bumbea, Otilia Constantina Rogoveanu, Adina Turcu-Stiolica, Ionica Pirici, George Cioroianu, Diana Iulia Stanca, Oana Criciotoiu, Viorel Biciusca, Rodica Magdalena Traistaru, Danut Visarion Caimac
Summary: The study highlights the role of botulinum toxin in spasticity therapy and functional recovery for stroke patients. The comparison between two groups, with one receiving botulinum toxin therapy and the other receiving medical rehabilitation, demonstrates that botulinum toxin therapy leads to better results in terms of upper limb recovery, functionality, and disability reduction.
Article
Food Science & Technology
Marco Battaglia, Margherita Beatrice Borg, Lara Torgano, Alberto Loro, Lucia Cosenza, Michele Bertoni, Alessandro Picelli, Andrea Santamato, Marco Invernizzi, Francesca Uberti, Claudio Molinari, Stefano Carda, Alessio Baricich
Summary: This study aimed to investigate the effects of Botulinum Neurotoxin type-A (BoNT-A) on post-stroke focal spasticity patients. The results showed that ultrasound-guided BoNT-A injection did not lead to contralateral muscle weakness or autonomic nervous system abnormalities. These findings support the existing literature on the safety of BoNT-A treatment.
Article
Rehabilitation
Cameron Lindsay, Ioan Humphreys, Ceri Phillips, Anand Pandyan
Summary: This study aimed to estimate the cost and consequences of early treatment with botulinum toxin for spasticity in the acute stroke unit. The analysis found that early treatment significantly reduced contracture costs and was more effective in improving function. Therefore, early intervention with botulinum toxin is important for stroke patients' rehabilitation.
CLINICAL REHABILITATION
(2023)
Article
Rehabilitation
Cameron Lindsay, Sissi Ispoglou, Brinton Helliwell, Dawn Hicklin, Steve Sturman, Anand Pandyan
Summary: In (hyper)acute stroke patients, early treatment with botulinum toxin can reduce spasticity, slow down contracture formation, increase passive range of motion, decrease splint use, and not interfere with the recovery of arm function.
CLINICAL REHABILITATION
(2021)
Article
Food Science & Technology
Alessandro Picelli, Andrea Santamato, Michela Cosma, Alessio Baricich, Carmelo Chisari, Marzia Millevolte, Cristina Del Prete, Ilenia Mazzu, Paolo Girardi, Nicola Smania
Summary: This study aimed to investigate the relationship between the timing of BoNT-A injection and treatment outcomes in PSS patients. The results showed that initiating BoNT-A treatment within 3 months post-stroke can lead to greater reduction in muscle tone at 1 and 3 months follow-up.
Article
Neurosciences
Hui-xian Yu, Si-hao Liu, Zhao-xia Wang, Chang-bin Liu, Pei Dai, Da-wei Zang
Summary: The study found that botulinum toxin type A injection can improve gait and posture control in patients with lower-limb spasticity post-stroke. It also improves motor functions and forefoot pressure in these patients.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Clinical Neurology
Jonathan Levy, Pierre Karam, Anne Forestier, Jean-Yves Loze, Djamel Bensmail
Summary: This study describes the use of intramuscular botulinum toxin type A (BoNT-A) for spasticity treatment in clinical practice in France between 2014 and 2020. The study found suboptimal implementation of BoNT-A treatment recommendations, with only 53.5% of patients receiving one or two BoNT-A injections and a low rate of initiation and re-administration of BoNT-A treatment in stroke survivors.
FRONTIERS IN NEUROLOGY
(2023)
Review
Food Science & Technology
Domenico Intiso, Antonello Marco Centra, Michele Gravina, Angelo Chiaramonte, Michelangelo Bartolo, Filomena Di Rienzo
Summary: Stroke patients with spasticity can benefit from high-dose BTX-A treatment, but the improvement in functional outcome and spasticity-related pain is still uncertain. Nine studies were analyzed, involving 460 subjects treated with high-dose BTX-A, with 301 of them having suffered from a stroke. Variable study designs and outcome measures were used, with only 55.5% reporting functional outcome data and 3 studies reporting the effect on spasticity-related pain. There is currently no definitive scientific evidence that supports the improvement in limb functionality with this therapeutic strategy, but certain patients may obtain goal-oriented improvement from high-dose BTX-A.
Article
Clinical Neurology
Massimo Marano, Antonio Suppa, Francesco Bono, Roberto Eleopra, Maria Concetta Altavista
Summary: This study presents the results of a survey conducted in Italy regarding the administration provisions of botulinum neurotoxin type A. The survey reveals a lack of standardized and shared administration protocols, leading to differences in public costs across different regions in Italy.
NEUROLOGICAL SCIENCES
(2023)
Article
Food Science & Technology
Jen-Wen Hung, Wen-Chi Wu, Yi-Ju Chen, Ya-Ping Pong, Ku-Chou Chang
Summary: Identifying patients who can achieve minimal clinically important difference in active motor function in the affected upper extremity after a botulinum toxin A injection is important. Factors such as time since stroke, Medical Research Council scale, post-injection duration, and education years are significant predictors of motor function improvement.
Article
Pharmacology & Pharmacy
Dimitrios N. Varvarousis, Dimitris Dimopoulos, George I. Vasileiadis, Ioannis Manolis, Avraam Ploumis
Summary: The study provides evidence that intramuscular injection of botulinum toxin is beneficial for patients suffering from spasticity due to chronic stroke, resulting in improvement in gait parameters and reduction in spasticity.
Article
Food Science & Technology
Yen-Ting Chen, Yang Liu, Chuan Zhang, Elaine Magat, Ping Zhou, Yingchun Zhang, Sheng Li
Summary: This study aimed to comprehensively assess the effects of Botulinum neurotoxin (BoNT) injection for managing focal spasticity in stroke survivors. The results showed that BoNT injection significantly reduced spasticity, muscle strength, reflex torque, and compound muscle action potential (CMAP) amplitude, and these effects returned to baseline levels after 3 months. Voluntary force control and non-reflex resistance torque were not affected.
Article
Medicine, General & Internal
Stefan Evers, Alexandra Buchheister, Doris Reichelt, Ingo W. Husstedt, Achim Frese
Summary: This study investigated the efficacy and safety of BTX treatment in HIV-infected patients. The results showed that BTX treatment was effective and well-tolerated in long-term use, with no interaction with antiretroviral treatment. Therefore, BTX treatment can be considered as an additional therapeutic option for HIV-infected patients.
JOURNAL OF CLINICAL MEDICINE
(2022)